No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
546 |
4. Check minimum number of eventsNone |
546 |
5. Include endpointsNone |
546 |
6. Filter based on genotype QC (FinnGen only) |
546 |
Control definitions (FinnGen only)
- Control exclude
- H8_INNER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H81
- Name in latin
- Vertigo centralis
Similar endpoints
↥List of similar endpoints to
Vertigo of central origin
based on the number of shared cases.
Similar with more cases:
- Disorders of vestibular function (Vertigo)
- Diseases of inner ear
- Diseases of the ear and mastoid process
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4801 | 3024 | 1740 |
| Only index persons | 3769 | 2372 | 1397 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.09 | 0.05 |
| Only index persons | 0.07 | 0.09 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 70.36 | 71.94 | 67.46 |
| Only index persons | 66.62 | 67.92 | 64.42 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 546 | 325 | 221 |
| Unadjusted period prevalence (%) | 0.11 | 0.11 | 0.10 |
| Median age at first event (years) | 62.07 | 60.16 | 64.88 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 499
- Matched controls
- 4988
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H81.4
ICD-10 Finland
Vertigo of central origin
4503599627370496.0
323.0
498
7
R42
ICD-10 Finland
Dizziness and giddiness
13.8
149.1
339
663
H81.1
ICD-10 Finland
Benign paroxysmal vertigo
12.5
60.6
115
117
H81.3
ICD-10 Finland
Other peripheral vertigo
49.8
57.5
69
16
DFF59
NOMESCO Finland
Other assessment of balance
126.4
43.5
46
*
AA1AD
NOMESCO Finland
CT of head and brain
3.8
37.3
207
786
H81.2
ICD-10 Finland
Vestibular neuronitis
372.0
35.4
35
*
N07CA01
ATC
betahistine; oral
6.2
32.0
93
179
H81.0
ICD-10 Finland
Ménière disease
42.3
22.9
28
7
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.1
22.6
76
171
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.3
21.5
69
147
DFF00
NOMESCO Finland
Pure tone audiometry
4.1
19.5
81
225
N17
ICPC
Vertigo/dizziness
3.5
18.6
94
308
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.8
17.8
62
144
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.2
16.5
95
341
SPAT1263
SPAT
Sampling
2.2
14.8
238
1482
H81.9
ICD-10 Finland
Disorder of vestibular function, unspecified
43.8
14.2
17
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.3
13.3
70
235
R51.80
ICD-10 Finland
Headache
2.8
13.1
89
354
SPAT1216
SPAT
Assessment of functional ability
2.5
12.7
111
510
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
12.5
117
556
DFF50
NOMESCO Finland
Electronystagmography
133.2
12.5
13
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.7
12.0
92
392
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
12.0
169
975
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
6.3
11.5
30
50
N02AX02
ATC
tramadol; systemic, rectal
2.0
11.5
233
1546
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
3.2
11.3
60
202
T90.5
ICD-10 Finland
Sequelae of intracranial injury
20.6
11.2
16
8
H02AB04
ATC
methylprednisolone; systemic
2.5
10.9
93
418
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
10.2
236
1614
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
2.2
10.2
111
565
N03AX16
ATC
pregabalin; oral
2.1
10.1
138
776
UDC00
NOMESCO Finland
Ear microscopy
3.4
10.0
49
156
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
9.9
105
525
N05AB04
ATC
prochlorperazine; systemic, rectal
5.2
9.9
30
61
R11
ICD-10 Finland
Nausea and vomiting
3.0
9.9
57
204
S06.0
ICD-10 Finland
Concussion
2.8
9.7
64
250
M01AE02
ATC
naproxen; oral, rectal
1.8
9.6
273
1989
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.3
9.6
101
503
R53
ICD-10 Finland
Malaise and fatigue
2.1
9.6
128
712
G44.2
ICD-10 Finland
Tension-type headache
2.5
9.5
76
331
B01AC07
ATC
dipyridamole; systemic
3.1
9.3
50
171
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
9.3
120
656
A02BC02
ATC
pantoprazole; systemic
1.8
9.2
326
2541
UKC02
NOMESCO Finland
Cystoscopy
2.2
9.2
103
530
N03AE01
ATC
clonazepam; systemic
3.5
9.2
42
127
A02BC05
ATC
esomeprazole; systemic
1.8
9.1
215
1466
NB1BA
NOMESCO Finland
Shoulder extensive X-ray examination without contrast
4.6
8.9
30
69
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.7
8.8
38
110
DAX00
NOMESCO Finland
Adjustment or review of hearing aid
3.5
8.8
40
121
M03BX02
ATC
tizanidine; oral
1.8
8.7
280
2095
SPAT1149
SPAT
Suture or treatment of traumatic wound
2.4
8.7
80
374
R07.4
ICD-10 Finland
Chest pain, unspecified
1.9
8.7
147
890
Z46.1
ICD-10 Finland
Fitting and adjustment of hearing aid
2.9
8.6
53
198
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
8.5
161
1014
H02AB07
ATC
prednisone; oral
2.3
8.5
84
407
I63.5
ICD-10 Finland
Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
7.6
8.5
19
26
SPAT1229
SPAT
Assessment of need for aid
2.7
8.3
59
239
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
7.3
8.3
19
27
TAB00
NOMESCO Finland
Lumbar puncture
4.0
8.3
32
84
N06AX11
ATC
mirtazapine; oral
1.8
8.2
160
1014
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.6
8.2
35
101
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.3
7.9
77
368
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.7
7.9
56
227
DE2CG
NOMESCO Finland
Acoustic channel extensive MRI examination with high intensity magnet
7.6
7.7
17
23
P76
ICPC
Depressive disorder
3.5
7.6
34
102
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.1
7.5
95
512
J37.0
ICD-10 Finland
Chronic laryngitis
4.7
7.5
24
53
DAX08
NOMESCO Finland
Fitting of hearing aid
3.4
7.5
35
109
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
7.8
7.4
16
21
SPAT1097
SPAT
Recording of ECG
2.1
7.4
89
469
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.8
7.4
170
1129
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.1
7.4
87
455
M54.5
ICD-10 Finland
Low back pain
1.8
7.4
160
1045
Z03.8
ICD-10 Finland
Observation for other suspected diseases and conditions
3.6
7.3
31
89
XKD06
NOMESCO Finland
Physiologic investigation of micturition
4.2
7.3
26
64
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.8
7.3
23
50
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.8
7.3
46
175
H25.8
ICD-10 Finland
Other senile cataract
2.1
7.3
82
422
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
3.1
7.2
38
129
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
7.2
171
1144
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.0
7.2
102
572
J01DA01
ATC
[U] cefalexin; systemic
1.7
7.1
302
2389
NH1AD
NOMESCO Finland
Ankle and foot CT
6.5
7.0
17
27
H82
ICPC
Vertiginous syndrome
5.6
7.0
19
35
G45.0
ICD-10 Finland
Vertebro-basilar artery syndrome
3.9
7.0
27
72
H53.2
ICD-10 Finland
Diplopia
4.5
6.9
23
53
A04
ICPC
Weakness/tiredness general
2.2
6.9
75
376
L28
ICPC
Limited function/disability (L)
2.0
6.9
98
550
N05BA12
ATC
alprazolam; oral
2.4
6.9
60
274
H53.1
ICD-10 Finland
Subjective visual disturbances
3.1
6.9
36
122
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
2.8
6.9
44
169
A03FA01
ATC
metoclopramide; systemic, rectal
1.9
6.9
110
648
N02BE01
ATC
paracetamol; systemic, rectal
1.9
6.7
420
3689
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.8
6.6
42
161
SPAT1312
SPAT
General health counselling
1.8
6.6
145
946
G35
ICD-10 Finland
Multiple sclerosis
7.0
6.6
15
22
R03BA05
ATC
fluticasone; inhalant
1.9
6.5
95
537
N03AF02
ATC
oxcarbazepine; oral
4.4
6.5
22
52
SPAT1254
SPAT
Administration of medicine
2.0
6.5
88
487
M53.0
ICD-10 Finland
Cervicocranial syndrome
2.5
6.5
48
200
SPAT1231
SPAT
Assessment of adjustments needed in living environment
4.8
6.5
20
43
DFF40
NOMESCO Finland
Otoneurologic examination of vertigo
70.7
6.4
7
*
SPAT1104
SPAT
Monitoring of emergency patient
2.6
6.3
44
177
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
1.6
6.3
190
1356
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.3
6.3
55
250
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
3.8
6.3
25
69
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.3
6.3
30
96
NA1BA
NOMESCO Finland
Cervical spine extensive X-ray examination without contrast
7.2
6.3
14
20
J01DB01
ATC
cefalexin; oral
1.7
6.2
381
3266
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.3
6.2
57
265
R51
ICD-10 Finland
Headache
3.2
6.2
30
97
N99
ICPC
Neurological disease other
7.8
6.2
13
17
G47.3
ICD-10 Finland
Sleep apnoea
1.9
6.1
101
600
N05CF01
ATC
zopiclone; oral
1.7
6.1
172
1203
NF1AA
NOMESCO Finland
Hip X-ray examination
2.3
6.1
55
256
A06AC01
ATC
ispaghula (psylla seeds); oral
1.7
6.1
134
872
N03AX09
ATC
lamotrigine; oral
3.8
6.1
24
66
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.6
6.0
42
168
M01AB51
ATC
indometacin, combinations; oral, rectal
4.7
6.0
19
42
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.0
6.0
79
431
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.3
6.0
28
88
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
165
539
3.96
43.96
5.0
4.6
32.7
32.2
%
0.24
109
358
309
1754
2.76
29.57
5.1
3.9
37.9
56.4
ng/l
0.44
247
1296
69
182
4.20
23.91
4.7
4.0
24.5
25.1
mmol/l
1.24
63
172
87
272
3.62
23.70
4.0
3.5
0.9
1.9
mmol/l
1.18
63
210
378
2567
2.54
22.23
4.8
4.5
6.8
6.7
mmol/l
0.13
355
2400
244
1366
2.42
22.15
2.3
2.1
135.2
247.1
u/l
1.28
231
1284
89
295
3.41
22.09
4.0
3.3
5.1
5.1
kpa
0.01
82
272
65
180
3.96
21.02
2.2
1.8
—
—
—
0
0
60
168
3.89
19.07
2.0
1.7
—
—
—
0
0
239
1461
2.13
16.23
3.2
3.1
1143.9
1520.4
ng/l
1.37
193
1248
357
2586
2.10
14.88
4.0
3.1
55.2
48.7
u/l
0.52
322
2393
278
1897
1.95
13.04
2.3
2.0
104.0
95.4
pmol/l
1.58
162
980
217
1362
1.99
13.00
3.1
2.4
58.1
56.6
u/l
0.11
195
1261
167
965
2.05
12.54
1.9
1.7
1053.9
1186.4
nmol/l
0.88
110
720
27
57
4.93
12.25
1.9
1.5
—
—
—
0
0
27
57
4.93
12.25
1.9
1.5
—
—
—
0
0
27
57
4.93
12.25
1.9
1.5
—
—
—
0
0
17
23
7.60
11.90
1.1
1.0
—
—
—
0
0
311
2245
1.90
11.90
6.7
6.4
1.2
1.2
mmol/l
0.80
253
1896
26
57
4.74
11.29
2.0
1.5
—
—
—
0
0
26
57
4.74
11.29
2.0
1.5
—
—
—
0
0
26
58
4.66
11.06
2.0
1.5
—
—
—
0
0
399
3174
1.96
10.82
5.5
4.1
13.5
13.0
mm/h
0.26
361
2906
27
65
4.32
10.47
1.7
2.9
43.0
28.0
mg/l
—
8
19
255
1778
1.82
10.42
2.5
2.3
80.4
77.8
nmol/l
0.72
215
1574
18
31
5.97
10.12
1.9
1.3
—
—
—
0
0
18
31
5.97
10.12
1.9
1.3
—
—
—
0
0
281
2039
1.78
9.86
5.8
5.6
1.2
1.2
mmol/l
0.89
232
1840
179
1140
1.85
9.68
1.7
1.6
20.8
20.8
nmol/l
0.01
144
963
68
301
2.44
9.66
1.9
1.6
—
—
—
0
0
168
1053
1.86
9.53
2.7
2.3
—
—
—
0
0
18
33
5.61
9.51
1.1
1.1
—
—
—
0
0
15
23
6.68
9.39
2.1
1.2
—
—
—
0
0
15
23
6.68
9.39
2.1
1.2
—
—
—
0
0
11
12
9.33
9.00
5.2
2.0
—
—
—
0
0
180
1173
1.80
8.90
2.5
2.1
3.1
3.2
mg/l
0.05
144
997
479
4193
2.18
8.24
20.6
15.2
17.8
24.5
mg/l
6.39
417
3341
58
258
2.40
8.14
2.6
2.5
—
17.1
—
0
10
356
2853
1.71
8.04
7.2
4.8
34.7
4643.7
e6/l
—
6
60
388
3193
1.75
7.86
4.9
4.0
15.3
14.9
pmol/l
2.35
335
2854
78
400
2.11
7.79
2.1
1.8
367.9
382.4
nmol/l
0.23
63
357
153
990
1.76
7.56
1.6
1.8
417.2
14662092.2
pmol/l
0.80
120
798
18
42
4.40
7.27
1.1
1.1
—
—
—
0
0
143
917
1.76
7.26
1.8
1.7
1.0
1.3
mg/l
0.82
101
711
29
99
3.04
6.80
2.1
1.4
—
—
—
0
0
13
24
5.52
6.80
2.3
2.3
—
—
—
0
0
17
41
4.25
6.59
1.1
1.1
—
—
—
0
0
15
34
4.51
6.27
1.0
1.2
—
81.8
—
0
6
62
318
2.07
6.17
1.8
1.6
—
—
—
0
0
395
3361
1.64
6.08
8.0
7.4
80.2
78.5
u/l
0.22
360
3140
34
136
2.60
5.98
1.7
1.2
—
—
—
0
0
440
3864
1.72
5.83
6.4
4.8
2.0
1.9
mu/l
0.30
384
3489
290
2323
1.53
5.60
5.8
6.1
10.6
11.6
umol/l
1.40
272
2201
117
758
1.69
5.59
2.2
1.9
—
—
—
0
0
104
658
1.72
5.41
1.2
1.2
9.3
12.1
u/ml
0.20
30
246
252
1971
1.52
5.36
4.1
4.3
35.0
35.0
g/l
0.04
218
1822
13
31
4.27
5.11
1.0
1.2
—
—
—
0
0
455
4078
1.70
5.04
6.0
4.8
6.1
6.0
mmol/l
1.21
386
3690
254
2008
1.50
5.04
4.1
4.0
—
—
—
0
0
29
118
2.54
4.96
1.4
1.5
—
—
—
0
0
17
51
3.41
4.92
1.2
1.1
1.0
12.4
iu/ml
—
5
9
477
4350
1.77
4.72
23.4
18.1
139.5
139.6
mmol/l
0.27
465
4234
38
180
2.19
4.66
1.8
1.9
1.2
3.5
ug/l
0.71
25
156
85
532
1.71
4.57
6.2
7.6
—
—
—
0
0
477
4362
1.75
4.51
23.4
18.2
4.0
4.0
mmol/l
0.29
463
4242
22
82
2.75
4.47
1.2
1.2
334.9
1470.0
e6/l
0.41
17
68
22
82
2.75
4.47
1.0
1.1
3.6
4.2
e6/l
0.12
16
66
437
3922
1.58
4.30
17.5
14.5
75.5
76.4
ml/min/173m2
0.41
378
3255
22
84
2.69
4.28
1.0
1.2
—
1.0
—
0
6
67
400
1.77
4.25
1.9
3.2
66.2
66.5
g/l
0.08
55
361
230
1829
1.45
4.21
3.0
2.7
129.4
132.4
ug/l
0.09
199
1667
124
870
1.55
4.20
1.4
1.2
3.3
1.8
u/ml
0.32
22
225
298
3446
0.70
3.99
21.6
18.7
13.9
13.8
%
0.18
291
3381
106
726
1.57
3.98
2.2
2.3
11.6
12.6
umol/l
0.72
94
665
98
660
1.59
3.95
2.2
2.3
2.4
2.3
g/l
0.29
85
606
276
2291
1.41
3.88
2.8
2.7
—
—
—
0
0
22
89
2.53
3.84
1.1
1.2
—
—
—
0
0
292
2451
1.41
3.84
7.2
8.9
4.3
4.1
e9/l
0.32
254
2146
433
3909
1.52
3.83
8.4
6.2
41.5
40.4
mmol/mol
1.68
376
3602
44
244
1.87
3.56
1.3
1.2
101.1
153.0
iu/ml
0.65
17
93
477
4420
1.63
3.56
13.1
10.6
24.9
24.6
u/l
0.11
453
4245
14
46
3.10
3.55
1.5
1.9
—
—
—
0
0
6
6
10.09
3.50
1.3
1.5
—
—
—
0
0
178
1389
1.42
3.47
4.6
3.9
10.9
8.2
mg/mmol
0.23
103
867
100
697
1.53
3.46
1.3
1.2
22.5
37.7
iu/ml
1.29
28
232
91
623
1.55
3.41
2.3
2.3
19.0
21.9
%
1.29
76
534
431
3917
1.48
3.41
5.0
4.0
1.3
1.3
mmol/l
0.81
378
3537
68
437
1.64
3.32
2.9
3.2
3.0
2.1
mmol/l
1.29
57
348
59
366
1.69
3.30
3.0
3.7
68.7
86.9
ng/l
1.19
45
319
36
192
1.94
3.28
1.0
1.0
—
—
—
0
0
13
43
3.07
3.27
1.5
2.0
—
—
—
0
0
9
20
4.56
3.12
1.8
2.0
—
—
—
0
0
9
20
4.56
3.12
1.8
2.0
—
—
—
0
0
9
20
4.56
3.12
1.8
2.0
—
—
—
0
0
32
167
1.97
3.11
1.6
2.1
33.6
41.7
u/l
1.46
27
147
89
621
1.52
3.06
28.2
25.5
1.8
1.3
inr
—
8
71
39
220
1.83
3.02
2.8
3.1
4.2
4.4
pmol/l
0.53
29
186
10
30
3.38
2.92
1.1
1.2
0.0
0.1
u/ml
—
5
17
100
723
1.47
2.90
2.2
3.1
0.8
0.8
mmol/l
0.27
86
675
83
579
1.51
2.86
4.8
4.7
1.0
1.0
mmol/l
0.06
73
520
487
4587
1.58
2.78
30.2
22.7
132.5
133.2
g/l
0.48
482
4502
7
14
5.05
2.73
1.3
1.5
—
—
—
0
0
247
2096
1.33
2.69
5.2
3.9
0.0
0.0
estimate
0.00
39
398
164
1310
1.36
2.68
5.1
5.1
3.7
2.6
ug/l
0.51
138
1145
9
25
3.64
2.58
1.8
1.8
—
—
—
0
0
9
25
3.64
2.58
1.8
1.8
—
—
—
0
0
9
25
3.64
2.58
1.8
1.8
—
—
—
0
0
9
25
3.64
2.58
1.8
1.8
—
—
—
0
0
5
7
7.20
2.55
1.0
1.1
—
—
—
0
0
5
7
7.20
2.55
1.0
1.1
—
—
—
0
0
141
1108
1.37
2.54
3.0
2.7
12261.7
8044.1
umol/l
0.30
120
945
25
129
1.98
2.54
1.5
1.5
223.4
275.8
ug/g
0.73
17
79
250
2141
1.31
2.50
5.1
4.0
0.0
0.0
estimate
0.00
37
390
246
2109
1.30
2.41
7.7
5.4
0.0
0.0
estimate
0.00
39
390
22
111
2.02
2.39
1.1
1.1
—
10.6
—
0
10
12
46
2.64
2.37
3.8
2.2
—
—
—
0
0
7
17
4.16
2.36
1.6
1.5
—
—
—
0
0
73
518
1.47
2.33
4.4
3.9
238.9
240.9
u/l
0.07
67
490
9
29
3.14
2.23
1.1
1.3
—
—
—
0
0
9
29
3.14
2.23
1.1
1.3
—
—
—
0
0
5
9
5.59
2.22
1.2
1.4
—
—
—
0
0
19
95
2.04
2.13
4.2
4.4
29.6
31.9
mg/l
—
10
62
24
131
1.87
2.11
1.5
1.6
—
—
—
0
0
163
1346
1.30
2.06
3.7
3.1
6.4
7.1
mmol/l
1.23
125
1116
434
4064
1.33
1.97
5.7
4.5
1.4
1.5
mmol/l
2.89
380
3702
5
11
4.58
1.94
1.2
1.1
—
—
—
0
0
26
150
1.77
1.94
3.0
3.5
—
—
—
0
0
54
376
1.48
1.92
5.5
6.3
10.7
10.4
mmol/l
0.09
48
351
398
3690
1.29
1.90
18.2
16.6
37.1
39.1
%
1.75
209
2482
436
4094
1.32
1.88
5.5
4.5
4.5
4.6
mmol/l
0.84
383
3755
38
246
1.59
1.87
2.7
3.0
0.2
0.2
e6/l
0.04
38
240
161
1343
1.28
1.86
2.6
3.0
30.9
32.2
u/l
0.29
146
1280
192
1639
1.26
1.84
5.7
4.2
—
—
—
0
0
5
12
4.19
1.82
1.0
1.2
—
—
—
0
0
16
80
2.03
1.81
2.3
2.3
16.6
15.2
%
—
8
34
444
4191
1.32
1.76
5.8
5.1
2.6
2.7
mmol/l
0.38
386
3818
6
18
3.36
1.75
1.0
1.2
—
—
—
0
0
8
31
2.60
1.66
1.0
1.2
—
—
—
0
0
70
911
0.73
1.63
2.8
3.0
2.4
2.5
mmol/l
0.48
59
787
5
14
3.59
1.62
2.2
1.2
—
—
—
0
0
34
224
1.55
1.58
1.4
2.0
1.7
1.5
g/l
0.73
28
195
183
1581
1.24
1.54
2.4
3.2
2.3
2.4
mmol/l
0.35
125
1347
5
16
3.14
1.44
2.0
1.3
140.0
114.3
nmol/l
—
5
9
29
189
1.56
1.43
1.6
2.5
—
—
—
0
0
29
189
1.56
1.43
1.6
2.5
3.5
3.7
g/l
0.20
14
133
29
189
1.56
1.43
1.6
2.5
7.4
7.5
g/l
0.22
18
138
9
41
2.21
1.37
1.8
1.7
—
—
—
0
0
9
41
2.21
1.37
1.8
1.7
—
—
—
0
0
9
41
2.21
1.37
1.8
1.7
—
—
—
0
0
19
112
1.72
1.37
1.1
1.4
—
—
—
0
0
182
1589
1.22
1.36
3.9
3.3
—
—
—
0
0
5
17
2.96
1.36
1.0
1.1
—
—
—
0
0
5
18
2.79
1.28
1.2
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
18
2.79
1.28
1.0
1.1
—
—
—
0
0
9
44
2.06
1.27
1.2
1.3
462.3
316.9
u/l
—
9
44
14
77
1.84
1.26
1.6
1.8
—
—
—
0
0
16
92
1.76
1.26
1.2
1.8
1116.1
24750.9
e6/l
—
9
67
16
92
1.76
1.26
3.0
3.5
23.9
424.3
u/ml
0.89
16
87
39
281
1.42
1.22
1.3
1.5
—
—
—
0
0
11
57
1.95
1.17
1.2
1.2
—
—
—
0
0
11
196
0.55
1.14
1.1
1.3
—
—
—
0
0
87
716
1.26
1.13
3.5
3.0
2.8
2.4
e6/l
0.19
58
393
26
176
1.50
1.12
1.7
2.6
2.8
3.2
g/l
1.03
15
135
51
395
1.32
1.05
1.9
2.4
4.4
5.4
ug/l
0.41
34
348
5
107
0.46
1.02
1.0
1.5
—
—
—
0
0
18
115
1.58
1.00
1.9
2.6
44.4
85.0
ug/min
—
9
63
0
29
0.00
0.98
0.0
1.6
—
10.6
—
0
16
20
133
1.52
0.95
1.5
1.6
—
—
—
0
0
9
51
1.78
0.95
1.2
1.1
—
—
—
0
0
54
430
1.28
0.93
2.5
2.1
0.2
0.2
g/l
0.07
49
402
9
52
1.74
0.92
1.9
1.6
—
—
—
0
0
16
102
1.59
0.91
1.5
2.2
7.5
7.8
kpa
0.28
16
90
16
103
1.57
0.88
1.6
1.7
—
—
—
0
0
11
64
1.73
0.86
2.5
2.4
—
777.4
—
0
5
16
105
1.54
0.82
1.5
1.7
—
—
—
0
0
13
81
1.62
0.82
2.2
1.9
12.8
5971.3
u/l
—
6
25
23
164
1.42
0.81
1.7
2.8
1.2
0.9
g/l
0.11
17
139
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
15
98
1.55
0.79
1.1
1.1
—
—
—
0
0
11
67
1.66
0.75
1.2
1.1
—
—
—
0
0
25
334
0.74
0.75
1.8
2.6
58.0
62.6
ml/min/173m2
—
10
134
24
177
1.37
0.72
1.6
2.6
10.0
10.5
g/l
0.20
17
147
7
40
1.76
0.71
1.4
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
137
1.40
0.65
1.7
2.3
0.5
0.4
u/ml
—
9
78
8
127
0.62
0.64
1.1
1.2
—
—
—
0
0
8
51
1.58
0.60
1.4
1.4
—
—
—
0
0
13
89
1.47
0.58
1.4
1.5
—
—
—
0
0
8
54
1.49
0.57
1.1
1.0
—
—
—
0
0
6
36
1.67
0.57
1.0
1.1
—
—
—
0
0
46
545
0.83
0.56
2.2
1.9
—
—
—
0
0
6
37
1.63
0.55
1.2
1.0
—
—
—
0
0
93
1038
0.87
0.55
4.2
4.4
23.6
21.5
%
0.49
53
504
8
126
0.63
0.55
1.1
1.2
—
—
—
0
0
67
588
1.16
0.50
1.4
1.4
—
—
—
0
0
13
93
1.41
0.48
1.2
1.4
—
—
—
0
0
8
119
0.67
0.46
1.9
1.5
—
—
—
0
0
95
864
1.12
0.43
4.9
3.8
107.8
310.0
ng/l
1.32
70
719
35
413
0.84
0.43
2.7
2.3
116.2
31.9
u/l
0.51
28
343
59
520
1.15
0.43
2.9
4.1
3.4
34.3
ug/l
1.29
43
439
5
32
1.57
0.42
1.0
1.6
—
275.0
—
0
6
5
32
1.57
0.42
1.8
1.2
—
—
—
0
0
8
58
1.38
0.41
1.4
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
2.4
—
0
6
48
547
0.87
0.40
2.2
1.8
—
—
—
0
0
19
152
1.26
0.37
2.8
3.8
—
1.5
—
0
13
9
125
0.72
0.35
1.7
1.3
26.3
28.8
iu/l
—
9
109
27
227
1.20
0.35
3.0
2.1
11.5
13.1
nmol/l
0.34
21
197
19
154
1.24
0.34
1.8
2.7
39.1
37.4
g/l
0.33
12
129
11
82
1.35
0.34
1.0
1.4
225.2
263.8
miu/ml
—
5
45
7
52
1.35
0.31
1.7
1.5
—
—
—
0
0
7
96
0.73
0.31
1.3
1.3
—
—
—
0
0
7
96
0.73
0.31
1.3
1.3
—
—
—
0
0
54
487
1.12
0.30
2.4
2.5
4.7
9.6
umol/l
5.45
45
413
83
768
1.10
0.29
3.4
2.8
1.0
1.1
e6/l
0.07
52
440
8
62
1.29
0.28
1.4
1.7
—
—
—
0
0
8
66
1.22
0.27
1.4
1.6
—
—
—
0
0
54
591
0.90
0.26
1.5
1.4
—
—
—
0
0
9
75
1.20
0.25
1.3
1.7
—
—
—
0
0
13
106
1.23
0.23
1.4
1.3
—
—
—
0
0
5
39
1.28
0.23
1.4
1.6
—
—
—
0
0
7
92
0.76
0.22
1.3
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
2.3
—
15.5
—
0
14
111
1162
0.94
0.19
5.2
4.2
0.0
0.0
estimate
0.00
37
380
13
109
1.20
0.18
1.2
1.3
—
—
—
0
0
8
73
1.10
0.15
1.3
1.2
—
42.1
—
0
7
9
81
1.11
0.15
1.7
1.5
308.0
312.2
mu/l
—
9
71
116
1119
1.05
0.14
1.7
1.6
1.4
1.3
mmol/l
0.19
98
921
8
100
0.80
0.13
1.9
1.6
—
—
—
0
0
9
110
0.82
0.13
1.8
1.4
—
—
—
0
0
11
127
0.86
0.12
1.6
1.7
—
—
—
0
0
6
54
1.11
0.09
1.0
1.0
—
—
—
0
0
7
68
1.03
0.08
1.0
1.3
—
—
—
0
0
41
392
1.05
0.07
1.5
1.7
1.6
1.5
%
0.12
35
335
122
1245
0.97
0.07
3.7
3.2
0.5
0.5
e6/l
0.00
95
935
93
951
0.97
0.06
5.9
4.3
1.0
1.0
kg/l
0.04
25
142
46
476
0.96
0.06
5.0
3.5
—
—
—
0
0
74
756
0.98
0.05
3.4
3.0
1.0
0.8
ug/l
0.42
57
510
51
524
0.97
0.04
4.2
6.4
1.7
1.3
mmol/l
0.34
32
411
25
258
0.97
0.02
1.8
1.8
—
—
—
0
0
10
97
1.03
0.00
1.6
2.0
—
—
—
0
0
27
273
0.99
0.00
1.4
1.7
—
—
—
0
0
28
283
0.99
0.00
1.8
1.9
—
—
—
0
0
5
49
1.02
0.00
1.2
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
58.3
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
55
0.91
0.00
2.0
4.4
—
—
—
0
0
5
51
0.98
0.00
1.2
2.2
86.3
78.9
u/ml
—
5
51
0
8
0.00
0.00
0.0
1.0
—
26.0
—
0
8
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
9.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
10.7
—
0
5
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H8_VERTIGOCENT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H8_VERTIGOCENT | 1.227 [1.11, 1.36] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.01 |
During the follow-up period (1.1.1998 — 31.12.2019), 1126 out of 2537 females with H8_VERTIGOCENT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H8_VERTIGOCENT | 1.266 [1.1, 1.45] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 670 out of 1498 males with H8_VERTIGOCENT died.
Mortality risk
Mortality risk for people of age
years, who have H8_VERTIGOCENT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.097% | 0.29% |
| 5 | 0.606% | 1.603% |
| 10 | 1.518% | 4.157% |
| 15 | 2.797% | 7.829% |
| 20 | 4.847% | 13.0% |
Relationships between endpoints
↥Index endpoint: H8_VERTIGOCENT – Vertigo of central origin
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data